HSBC noted that while the market has assumed a significant market share for Eli Lilly, these expectations may be revised in light of potential economic sensitivity to the adoption curve for weight loss drugs.
The $150 billion investment will include more than $30 billion in research and development to advance and continue IBM's American manufacturing of mainframe and quantum computers.
For the full year, Revvity raised its revenue guidance to a range of $2.83 billion to $2.87 billion to reflect recent changes in foreign currency exchange rates.
Bernstein stated that after high Federal Aviation Administration (FAA) scrutiny, Boeing Commercial Airplanes "should be on a much firmer path than in 2023.”
The company now expects the health benefits ratio for the full year to be in the range of 88.9% to 89.5%, up from its previous guidance of 88.4% to 89%.
The company’s immunology drugs, Skyrizi and Rinvoq, marked significant revenue growth, offsetting a 50.6% decrease in net revenue from its arthritis drug, Humira.
